Tag: Mesoblast

June 11, 2019

Mesoblast and JCR Pharmaceuticals Expand Japan License Agreement

Mesoblast (NASDAQ:MESO, ASX:MSB) has announced it has expanded its partnership with JCR Pharmaceuticals for its use of mesenchymal stem cells...
March 25, 2019

Mesoblast Licensee Files for Marketing Approval to Treat Epidermolysis Bullosa

Mesoblast (NASDAQ:MESO,ASX:MSB) has announced its licensee in Japan, JCR Pharmaceuticals, has filed to extend marketing approval for TEMCELL HS for...
January 14, 2019

Hercules Capital Provides US$15M From Existing Facility for Mesoblast to Accelerate Product Commercialization Programs

Mesoblast (ASX:MSB;Nasdaq:MESO) today announced that it has drawn down a further US$15 million from its US$75 million, non-dilutive, four-year credit...
December 26, 2018

5 Top Genetics News Stories of 2018

What caught the attention of readers in the genetics market this year? We've compiled a list of our top genetics...
November 16, 2018

Mesoblast Reports First Quarter Ended September 30, 2018 Financial Results and Operational Highlights

Mesoblast (ASX:MSB; NASDAQ:MESO) today reported strong financial results and provided operational highlights for the first quarter ended September 30, 2018....
September 25, 2018

Investing in Stem Cell Treatments

Stem cell treatments have grabbed investor attention for years, but can be complex and potentially dangerous. Here is an overview...
April 29, 2018

5 Top Weekly NASDAQ Biotech Stocks: Eleven Biotherapeutics Up 45 Percent

Eleven Biotherapeutics, EyePoint Pharmaceuticals, Avid Bioservices, Cerecor and Celldex were last week's top gainers on the NASDAQ.